Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae

Bone

Volumn 25, Issue 6, 1999, Pages 703-712

  Kobayashi, S ^a   Shimizu, T ^a   Mehdi, R ^a   Nawata, M ^a   Kojima, S ^a   Tsutsumimoto, T ^a   Iorio, R ^b   Takaoka, K ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Biomechanics; Bisphosphonate; Estrogen; Histomorphometry; Parathyroid hormone (PTH); Rat

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; INCADRONIC ACID; PARATHYROID HORMONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE TURNOVER; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TRABECULAR BONE; VERTEBRA; VERTEBRA BODY;

ANIMALS; BIOMECHANICS; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; DIPHOSPHONATES; DRUG SYNERGISM; ESTRADIOL; HUMANS; LUMBAR VERTEBRAE; MALE; PARATHYROID HORMONE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 0032695810     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00219-7     Document Type: Article

References (63)

1. Baron R., Tross R., Vignery A. Evidence of sequential remodeling in rat trabecular bone Morphology, dynamic histomorphometry, and changes during skeletal maturation . Anat Rec. 208:1984;137-145.
2. Baumann B.D., Wronski T.J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone. 16:1995;247-253.
3. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
4. 3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res. 11:1996;600-613.
5. Christiansen C., Christensen M.S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. i:1981;459-461.
6. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nillssen M.H.L. The anabolic effect of human PTH(1-34) or bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone. 16:1995;603-610.
7. Ejersted C., Andreassen T.T., Oxlund H., et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res. 8:1993;1097-1101.
8. Erben R.G. Trabecular and endocortical bone surfaces in the rat Modeling or remodeling? Anat Rec. 246:1996;39-46.
9. Finkelstein J.S., Klibanski A., Schaefer E.H., et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 331:1994;1618-1623.
10. Garnero P., Sornay-Rendu E., Chapuy M.-C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 11:1996;337-349.
11. Garrahan N.J., Mellish R.W.E., Compston J.E. A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J Microsc. 142:1986;341-349.
12. Günzel P. Animal toxicity test methods for hormonal contraceptives. Plotz E.J., Haller J. Methods in Steroid Toxicology Report of a Workshop Held in Bonn, December 1970 . 1970;77-81 Geron-X, Los Altos, CA.
13. Hesch R.D., Heck J., Delling G., et al. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP Protocol of study I, osteoporosis trial Hannover . Klin Wochenschr. 66:1988;976-984.
14. Hesp R., Hulme P., Williams D., Reeve J. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34). Metab Bone Dis Rel Res. 2:1981;331-334.
15. Hock J.M., Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 7:1992;65-72.
16. Hodsman A.B., Fraher L.J. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. Bone Miner. 9:1990;137-152.
17. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., Steer B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest. 91:1993;1138-1148.
18. Hodsman A.B., Steer B.M., Fraher L.J., Drost D.J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 14:1991;67-83.
19. Ibbotson K.J., Orcutt C.M., D'Souza S.M., et al. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. J Bone Miner Res. 7:1992;425-432.
20. Inoue J. Bone changes with long term administration of low dose 1-34 human PTH on adult beagles. J Jpn Orthop Assoc. 59:1985;409-427.
21. Jee W.S.S., Inoue J., Jee K.W., Haba T. Histomorphometric assay of the growing long bone. Takahashi H. Handbook of Bone Morphology. 1983;101-122 Nishimura, Niigata, Japan.
22. Jee W.S.S., Mori S., Li X.J., Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone. 11:1990;253-266.
23. Kalu D.N., Echon R., Hollis B.W. Modulation of ovariectomy-related bone loss by parathyroid hormone in rats. Mech Aging Devel. 56:1990;49-62.
24. Kimmel D.B., Jee W.S.S. A quantitative histologic analysis of the growing long bone metaphysis. Calcif Tissue Int. 32:1980;113-122.
25. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
26. Lindsay R., Hart D.M., Aitken J.M., et al. Long-term prevention of postmenopausal osteoporosis by oestrogen Evidence for an increased bone mass after delayed onset of oestrogen treatment . Lancet. i:1976;1038-1041.
27. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 350:1997;550-555.
28. Liu C.C., Kalu D.N. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res. 5:1990;973-982.
29. Ma Y.F., Jee W.S.S., Ke H.Z., et al. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J Bone Miner Res. 1:1995;496-505.
30. Mashiba T., Tanizawa T., Takahashi H.E., et al. Effects of single and concurrent intermittent administration of human parathyroid hormone and bisphosphonate cimadronate on bone mineral densities of femur in ovariectomized rats. J Bone Miner Metab. 13:1995;17-22.
31. Mellish R.W.E., Ferguson-Pell M.W., Cochran G.V.B., Lindsay R., Dempster D.W. A new manual method for assessing two-dimensional cancellous bone structure Comparison between iliac crest and lumbar vertebra . J Bone Miner Res. 6:1991;689-696.
32. Melton L.J. III. How many women have osteoporosis now? J Bone Miner Res. 10:1995;175-177.
33. Meng X.W., Liang X.G., Birchman R., et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res. 11:1996;421-429.
34. Merz W.A., Schenk R.K. Quantitative structural analysis of human cancellous bone. Acta Anat. 75:1970;54-66.
35. Mitlak B.H., Burdette-Miller P., Schoenfeld D., Neer R.M. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. J Bone Miner Res. 11:1996;430-439.
36. Mosekilde L., Danielsen C.C., Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combined therapy, assessed in aged ovariectomized rats. Endocrinology. 134:1994;2126-2134.
37. Mosekilde L., Søgaard C.H., McOsker J.E., Wronski T.J. PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate) Assessed in sexually mature, ovariectomized rats . Bone. 15:1994;401-408.
38. 3. Bone. 10:1989;117-123.
39. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry Standardization of nomenclature, symbols and units . J Bone Miner Res. 2:1987;595-610.
40. Podbesek R., Edouard C., Meunier P.J., et al. Effects of two treatment regimens with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology. 112:1983;1000-1006.
41. Qi H., Li M., Wronski T.J. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res. 6:1995;948-955.
42. Reeve J., Arlot M., Bernat M., et al. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis The influence of human parathyroid fragment (hPTH 1-34) therapy . Metab Bone Dis Rel Res. 3:1981;23-30.
43. Reeve J., Bradbeer J.N., Arlot M., et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy Biochemical, kinetic and histological responses . Osteopor Int. 1:1991;162-170.
44. Reeve J., Meunier P.J., Parsons J.A., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis A multicentre trial . Br Med J. 280:1980;1340-1344.
45. Riggs B.L., Melton L.J. III. Involutional osteoporosis. N Engl J Med. 314:1986;1676-1686.
46. Shen V., Dempster D.W., Birchman R., Xu R., Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest. 91:1993;2479-2487.
47. Shen V., Dempster D.W., Mellish R.W.E., Birchman R., Horbert W., Lindsay R. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int. 50:1992;214-220.
48. Søgaard C.H., Wronski T.J., McOsker J.E., Mosekilde L. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology. 134:1994;650-657.
49. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sørensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med. 322:1990;1265-1271.
50. Tada K., Yamamuro T., Okumura H., Kasai R., Takahashi H. Restoration of axial and appendicular bone volumes by h-PTH(1-34) in parathyroidectomized and osteopenic rats. Bone. 11:1990;163-169.
51. Takahashi H.E., Tanizawa T., Hori M., Uzawa T. Effect of intermittent administration of human parathyroid hormone (1-34) on experimental osteopenia of rats induced by ovariectomy. Jee W.S.S. The Aged Rat Model for Bone Biology Studies. Cells and Materials. 1991;113-117 Scanning Microscopy International, Chicago.
52. Tam C.S., Heersche J.N.M., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action Differential effects of intermittent and continuous administration . Endocrinology. 110:1982;506-512.
53. Effects of hormone therapy on bone mineral density Results from the postmenopausal estrogen/progestin interventions (PEPI) Trial . JAMA. 276:1996;1389-1396.
54. Turner C.H., Burr D.B. Basic biomechanical measurements of bone A tutorial . Bone. 14:1993;595-608.
55. Uzawa T., Hori M., Ejiri S., Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone. 16:1995;477-484.
56. Villanueva A.R. A bone stain for osteoid seams in fresh unembedded, mineralized bone. Stain Technol. 49:1974;1-8.
57. Wronski T.J., Cintron M., Doherty A.L., Dann L.M. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology. 123:1988;681-686.
58. Wronski T.J., Dann L.M., Scott K.S., Cintrón M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int. 45:1989;360-366.
59. Wronski T.J., Lowry P.L., Walsh C.C., Ignaszewski L.A. Skeletal alterations in ovariectomized rats. Calcif Tissue Int. 37:1985;324-328.
60. Wronski T.J., Walsh C.C., Ignaszewski L.A. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone. 7:1986;119-123.
61. Wronski T.J., Yen C.-F. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone. 15:1994;51-58.
62. Wronski T.J., Yen C.-F., Qi H., Dann L.M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 132:1993;823-831.
63. Zhang L., Takahashi H.E., Tanizawa T., Endo N., Yamamoto N. Maintenance of bone mineral density of femoral cortex in ovariectomized rats after withdrawal of concurrent administration of human parathyroid hormone (1-34) and incadronate disodium (YM175). J Bone Miner Metab. 15:1997;206-212.